Cargando…

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists

Detalles Bibliográficos
Autores principales:	Drillet, Gaëlle, Lhomme, Faustine, De Guibert, Sophie, Manson, Guillaume, Houot, Roch
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979763/ https://www.ncbi.nlm.nih.gov/pubmed/35930692 http://dx.doi.org/10.1182/bloodadvances.2022008066

Ejemplares similares

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy
por: Nair, Ranjit, et al.
Publicado: (2020)

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
por: Bastida, José María, et al.
Publicado: (2021)

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
por: Garzon, Angelica Maria, et al.
Publicado: (2015)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
por: Nilles, Kathy M., et al.
Publicado: (2019)

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
por: Baur, Rebecca, et al.
Publicado: (2021)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
por: Shin, Jiwon, et al.
Publicado: (2023)

P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL LIFE?
por: Perthus, Alya, et al.
Publicado: (2023)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
por: Roy, Sayak
Publicado: (2019)

Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
por: Agarwal, Nikki, et al.
Publicado: (2021)

P1407: REMOTE MONITORING OF CAR T-CELL TREATED PATIENTS BY A SPECIALIZED NURSE TO DETECT AND MANAGE LATE COMPLICATIONS: REPORT OF THE CARAMA PROGRAM
por: Colin, Fanny, et al.
Publicado: (2023)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
por: Guo, Jian-Chun, et al.
Publicado: (2017)

Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Thrombopoietin levels in Quebec platelet disorder—Implications for the mechanism of thrombocytopenia
por: Hayward, C. P. M., et al.
Publicado: (2018)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
por: Carpenedo, Monica, et al.
Publicado: (2021)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
por: Sayed, Gamal, et al.
Publicado: (2023)

Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis
por: Chen, Wen, et al.
Publicado: (2023)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
por: Nakai, Kensaku, et al.
Publicado: (2022)

Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
por: Wang, Li, et al.
Publicado: (2016)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
por: Lozano, Maria L., et al.
Publicado: (2019)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022)

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
por: Pulanić, Dražen, et al.
Publicado: (2023)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence
por: Qureshi, Kamran, et al.
Publicado: (2016)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
por: Mei, Heng, et al.
Publicado: (2021)

P1636: PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY).
por: Jansen, A. G., et al.
Publicado: (2022)

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review
por: Teekaput, Chutithep, et al.
Publicado: (2022)

The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity
por: Hamed, Eman Mostafa, et al.
Publicado: (2023)

P1629: DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE
por: Santano, Ana María Mena, et al.
Publicado: (2023)

Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy
por: Napolitano, Mariasanta, et al.
Publicado: (2023)

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
por: Cuker, Adam, et al.
Publicado: (2020)

Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
por: Lozano, Maria L., et al.
Publicado: (2021)

T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
por: Messéant, Ondine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pnadadrfk7gsldabjtqion1jf7